Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2020; 10(11): 18-26


Molecular docking study of Xanthyl Chalcone derivatives as potential inhibitor agents against KIT tyrosine kinase and KIT kinase domain mutant D816H

Muthia Rahayu Iresha, Jumina Jumina, Harno Dwi Pranowo.




Abstract
Cited by 4 Articles

The mutation of D816H that occurs in the tyrosine kinase protein is responsible for gastrointestinal stromal tumors (GISTs). The mutation is commonly followed by the formation of a protein-resistant expression, thus new inhibitor agents are highly required in the near future. Molecular docking studies were carried out to evaluate the inhibition activity of six xanthyl chalcone derivatives to the wild and mutant types of KIT tyrosine kinase protein. The results showed that six xanthyl chalcone derivatives gave strong binding interactions with both tyrosine kinase proteins yielding on binding energy of −8.45 to −11.8 kcal mol−1, respectively. The molecular docking studies confirm that the binding interactions between the xanthyl chalcone and the amino acid residue were similar to those of sunitinib as the native ligand. Among all xanthyl chalcone derivatives, compound X6 possessed the lowest free binding energy value. Thus, compound X6 possibly has the highest inhibition activity toward wildtype and D816H mutant KIT protein. X6 was observed successfully to bind the activated KIT tyrosine kinase active site with a low binding energy value of −11.22 kcal mol−1. Therefore, this compound could become a promising inhibition agent to treat GIST

Key words: Molecular docking, gastrointestinal stromal tumors, KIT kinase domain, KIT kinase domain mutant D816H, xanthylchalcone






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.